当前位置： SCI文献检索 > Clinical Lung Cancer期刊下所有文献 > Results from a single institution phase II trial of concurrent docetaxel/carboplatin/radiotherapy followed by surgical resection and consolidation docetaxel/carboplatin in stage III non-small-cell lung cancer.

Results from a single institution phase II trial of concurrent docetaxel/carboplatin/radiotherapy followed by surgical resection and consolidation docetaxel/carboplatin in stage III non-small-cell lung cancer.

Abstract：

BACKGROUND:The optimal treatment of locally advanced non-small-cell lung cancer (NSCLC) remains controversial. We hypothesized that using a trimodality approach in selected patients with stage IIIA/IIIB disease would be both feasible and efficacious with reasonable toxicity. PATIENTS/METHODS:We enrolled 13 patients with resectable stage III NSCLC on a prospective phase II trial of trimodality therapy. Induction treatment consisted of weekly docetaxel 20 mg/m(2) and weekly carboplatin at an area under curve (AUC) of 2 concurrent with 45 Gy thoracic radiotherapy. Resection was performed unless felt to be unsafe or if patients had progressive disease. Postoperative consolidation consisted of docetaxel 75 mg/m(2) and carboplatin at an AUC of 6 every 3 weeks for 3 cycles with growth factor support. RESULTS:All patients responded to induction chemoradiotherapy as measured by total gross tumor volume reductions of 43% on average (range, 27%-64%). Twelve patients underwent resection of the tumor and involved nodes, yielding a resectability rate of 92%. The primary endpoint of 2-year overall survival (OS) was 72% (95% confidence interval [CI], 36%-90%), and 2-year progression-free survival (PFS) was 36% (95% CI, 9%-64%). The maximal toxicity observed per patient was grade II in 5 patients (38%); grade III in 7 patients (54%); grade IV in 1 patient (8%); and grade V in none. CONCLUSION:This trimodality approach resulted in promising outcomes with reasonable toxicity in carefully selected patients with stage III NSCLC at a single institution.

journal_name

Clin Lung Cancer

journal_title

Clinical lung cancer

authors

Das M,Donington JS,Murphy J,Kozak M,Eclov N,Whyte RI,Hoang CD,Zhou L,Le QT,Loo BW,Wakelee H

doi

10.1016/j.cllc.2011.06.003

subject

Has Abstract

pub_date

2011-09-01 00:00:00

pages

280-5

issue

5

eissn

1525-7304

issn

1938-0690

pii

S1525-7304(11)00138-0

journal_volume

12

pub_type

杂志文章

相关文献

Clinical Lung Cancer文献大全
  • RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma.

    abstract：:Thymic epithelial tumors are rare malignancies. Thymic carcinoma represents about 20% of all thymic epithelial tumors and has aggressive behavior, with a greater tendency to metastatic spread. Thymic carcinoma is often diagnosed in advanced stages for which systemic treatment is the main therapeutic option. The associ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.cllc.2018.06.005

    authors： Imbimbo M,Vitali M,Fabbri A,Ottaviano M,Pasello G,Petrini I,Palmieri G,Berardi R,Zucali P,Ganzinelli M,Marabese M,Broggini M,Marino M,Trama A,Rulli E,Hollander L,Pruneri G,Torri V,Garassino MC

    更新日期：2018-09-01 00:00:00

  • Concurrent chemoradiotherapy for patients with postoperative recurrence of surgically resected non-small-cell lung cancer.

    abstract：BACKGROUND:A few reports have evaluated the outcomes of concurrent chemoradiotherapy (CRT) for patients with postoperative recurrence of non-small cell lung cancer (NSCLC). PATIENTS AND METHODS:From 2000 through 2011, 1237 consecutive patients with NSCLC underwent pulmonary resection at our institution. Of those, 280 ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2014.06.001

    authors： Takenaka T,Takenoyama M,Toyozawa R,Inamasu E,Yoshida T,Toyokawa G,Shiraishi Y,Hirai F,Yamaguchi M,Seto T,Ichinose Y

    更新日期：2015-01-01 00:00:00

  • Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy.

    abstract：BACKGROUND:The real-world effect of anti-programmed death ligand 1 (PD-L1) therapies is unclear. We compared US patients who received second-line therapy for non-small-cell lung cancer (NSCLC) before and shortly after US Food and Drug Administration (FDA) approval of PD-L1 inhibitors. PATIENTS AND METHODS:Patients in ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2019.04.004

    authors： Schwartzberg L,Korytowsky B,Penrod JR,Zhang Y,Le TK,Batenchuk C,Krug L

    更新日期：2019-07-01 00:00:00

  • Patients with lung cancer with metachronous or synchronous gastric cancer.

    abstract：BACKGROUND:There are few reports of treatment and outcome for patients with metachronous or synchronous lung and gastric cancers. To evaluate them, we conducted a retrospective study. PATIENTS AND METHODS:The medical records of patients with lung cancer who previously or simultaneously had gastric cancer seen in our d...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/CLC.2009.n.079

    authors： Kurishima K,Satoh H,Kagohashi K,Homma S,Nakayama H,Ohara G,Ishikawa H,Hizawa N

    更新日期：2009-11-01 00:00:00

  • Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505).

    abstract：:Radiation Therapy Oncology Group (RTOG) 3505 is a randomized phase 3 study of concurrent chemoradiation followed by immune checkpoint inhibitor therapy or placebo in patients with locally advanced non-small-cell lung cancer (NSCLC). Patients with surgically unresectable stage 3 NSCLC will receive thoracic radiotherapy...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.cllc.2016.10.009

    authors： Gerber DE,Urbanic JJ,Langer C,Hu C,Chang IF,Lu B,Movsas B,Jeraj R,Curran WJ,Bradley JD

    更新日期：2017-05-01 00:00:00

  • Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab.

    abstract：BACKGROUND:Cancer-associated macrophage-like cells (CAMLs) are a potential peripheral blood biomarker for disease progression. This study used data from a phase 2 clinical trial to evaluate prognostic utility of CAMLs for locally advanced non-small-cell lung cancer treated with definitive chemoradiotherapy (CRT) and at...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2020.06.016

    authors： Augustyn A,Adams DL,He J,Qiao Y,Verma V,Liao Z,Tang CM,Heymach JV,Tsao AS,Lin SH

    更新日期：2020-06-20 00:00:00

  • Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.

    abstract：:Activating mutations in the epidermal growth factor receptor (EGFR) gene are extremely rare in small-cell lung cancer (SCLC). Here, we present a case of an EGFR-mutant gefitinib-responsive non-small-cell lung cancer (NSCLC) of adenocarcinoma histology occurring in a never-smoker followed by subsequent diagnosis of met...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/CLC.2010.n.046

    authors： Alam N,Gustafson KS,Ladanyi M,Zakowski MF,Kapoor A,Truskinovsky AM,Dudek AZ

    更新日期：2010-09-01 00:00:00

  • Comparison of Radiotherapy and Chemoradiotherapy for Locoregional Recurrence of Non-small-cell Lung Cancer Developing After Surgery.

    abstract：BACKGROUND:The optimal treatment strategy for locoregional recurrences developing after surgical resection in patients with non-small-cell lung cancer (NSCLC) is yet to be clearly established. PATIENTS AND METHODS:To investigate the efficacy and safety of radiotherapy (RT) and chemoradiotherapy (CRT), we reviewed the ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2017.05.005

    authors： Nakamichi S,Horinouchi H,Asao T,Goto Y,Kanda S,Fujiwara Y,Nokihara H,Yamamoto N,Ito Y,Watanabe SI,Ohe Y

    更新日期：2017-11-01 00:00:00

  • Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity.

    abstract：:Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatic dermatologic side effects. Skin rash is the dose-limiting factor for all EGFR inhibitors and is usually dose related and reversible. Microbiologic stains and cultures from skin rash usually do not show an infectious cause. We re...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/CLC.2008.n.010

    authors： Grenader T,Gipps M,Goldberg A

    更新日期：2008-01-01 00:00:00

  • Incidental Diagnosis of Asymptomatic Non-Small-Cell Lung Cancer: A Registry-Based Analysis.

    abstract：INTRODUCTION:Clinical manifestation of non-small-cell lung cancer (NSCLC) mainly occurs at advanced stages. Thus, the scientific community is evaluating different screening programs in high-risk patients to detect NSCLC at an earlier stage to improve survival. However, up to now patient selection and modalities have be...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2015.08.006

    authors： Kocher F,Lunger F,Seeber A,Amann A,Pircher A,Hilbe W,Fiegl M

    更新日期：2016-01-01 00:00:00

  • Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.

    abstract：INTRODUCTION:The programmed death 1 antibodies (PD-1 Ab) nivolumab and pembrolizumab improve overall survival (OS) in advanced non-small-cell lung cancer (NSCLC). We evaluated the correlation between immune-related adverse events (irAE) and treatment interruption due to irAE on clinical efficacy of PD-1 Ab in advanced ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.cllc.2018.09.005

    authors： Ksienski D,Wai ES,Croteau N,Fiorino L,Brooks E,Poonja Z,Fenton D,Geller G,Glick D,Lesperance M

    更新日期：2019-01-01 00:00:00

  • A phase II study of topotecan in patients with relapsed small-cell lung cancer.

    abstract：:An early phase II study of topotecan produced favorable results in a small number of untreated and previously treated patients with small-cell lung cancer (SCLC). This multicenter study was conducted in patients with relapsed SCLC at 19 medical institutions in Japan. Topotecan 1.0 mg/m2/day was administered for 5 cons...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/clc.2003.n.002

    authors： Takeda K,Negoro S,Sawa T,Nakagawa K,Kawahara M,Isobe T,Kudoh S,Masuda N,Niitani H,Fukuoka M

    更新日期：2003-01-01 00:00:00

  • Cooperative group research endeavors in small-cell lung cancer: current and future directions.

    abstract：:The International Lung Cancer Congress (ILCC), now in its ninth year, is a key forum for representatives of cooperative groups in North America, Europe, and Japan to discuss ongoing and planned clinical trials in lung cancer. Many of the significant strides in lung cancer treatment often originate from investigations ...

    journal_title：Clinical lung cancer

    pub_type：

    doi：10.3816/CLC.2009.n.044

    authors： Sangha R,Lara PN Jr,Adjei AA,Baas P,Choy H,Gaspar LE,Goss G,Saijo N,Schiller JH,Vokes EE,Gandara DR

    更新日期：2009-09-01 00:00:00

  • Stereotactic Body Radiotherapy for Early-Stage Multiple Primary Lung Cancers.

    abstract：BACKGROUND:Patients with multiple primary lung cancers increasingly receive multiple courses of stereotactic body radiotherapy (SBRT). We aimed to clarify the efficacy and safety of such treatments. PATIENTS AND METHODS:We reviewed a prospective lung SBRT database of patients treated for stage I non-small-cell lung ca...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2018.10.010

    authors： Nikitas J,DeWees T,Rehman S,Abraham C,Bradley J,Robinson C,Roach M

    更新日期：2019-03-01 00:00:00

  • Second Primary Non-Small-Cell Lung Cancer After Head and Neck Cancer: A Population-Based Study of Clinical and Pathologic Characteristics and Survival Outcomes in 3597 Patients.

    abstract：INTRODUCTION:Retrospective studies have shown an increased risk of second primary lung cancer in patients with a history of head and neck cancer (HNC). No population-based study has examined the overall survival (OS) outcomes of patients with second primary non-small-cell lung cancer (NSCLC) after HNC comparison with p...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2019.02.017

    authors： Budnik J,DeNunzio NJ,Singh DP,Milano MT

    更新日期：2020-05-01 00:00:00

  • ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection.

    abstract：INTRODUCTION:Currently, the role of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as adjuvant therapy for early-stage non-small-cell lung cancer after complete surgical tumor resection remains under investigation. We present the rationale and study design for the ADAURA (ClinicalTrials.gov identifi...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.cllc.2018.04.004

    authors： Wu YL,Herbst RS,Mann H,Rukazenkov Y,Marotti M,Tsuboi M

    更新日期：2018-07-01 00:00:00

  • First-line chemotherapy for advanced-stage non-small-cell lung cancer: focus on docetaxel.

    abstract：:Systemic chemotherapy results in modest improvements in survival and quality of life for patients with advanced-stage non-small-cell lung cancer (NSCLC). Administration of a platinum compound in combination with a taxane (paclitaxel or docetaxel), gemcitabine, vinorelbine, or irinotecan is considered optimal first-lin...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.3816/clc.2005.s.014

    authors： Ramalingam S

    更新日期：2005-12-01 00:00:00

  • ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer.

    abstract：BACKGROUND:ROS1 gene fusions cause several cancers by constitutively activating the ROS1 tyrosine kinase receptor. ROS1-targeted inhibitor therapy improves survival in the approximately 1% to 2% of patients with lung adenocarcinoma with ROS1 gene fusions. Although fluorescence in situ hybridization (FISH) is the standa...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2014.10.003

    authors： Boyle TA,Masago K,Ellison KE,Yatabe Y,Hirsch FR

    更新日期：2015-03-01 00:00:00

  • Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.

    abstract：BACKGROUND:Afatinib is approved in the US, Europe, and several other regions for first-line treatment for epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:Treatment-naive patients with advanced EGFRm+ NSCLC were randomized to afatinib (40 mg/d) versus...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.cllc.2018.03.009

    authors： Wu YL,Sequist LV,Tan EH,Geater SL,Orlov S,Zhang L,Lee KH,Tsai CM,Kato T,Barrios CH,Schuler M,Hirsh V,Yamamoto N,O'Byrne K,Boyer M,Mok T,Peil B,Märten A,Chih-Hsin Yang J,Paz-Ares L,Park K

    更新日期：2018-07-01 00:00:00

  • Tirapazamine with cisplatin and vinorelbine in patients with advanced non-small-cell lung cancer: a phase I/II study.

    abstract：:This phase I/II study was conducted to evaluate the safety and efficacy of tirapazamine in combination with cisplatin and vinorelbine for patients with advanced-stage IIIB/IV chemonaive non-small-cell lung cancer. Seventy patients with a Karnofsky performance status of > or = 60% were included. In the phase I part of ...

    journal_title：Clinical lung cancer

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.3816/clc.2005.n.008

    authors： Gatineau M,Rixe O,Chevalier TL

    更新日期：2005-03-01 00:00:00

  • Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC).

    abstract：BACKGROUND:Serum tumor markers are considered a negative prognostic factor in early-stages NSCLC but its role in advanced disease is controversial. The aim of this study is to analyze the prognostic value of tumor markers in advanced NSCLC. PATIENTS AND METHODS:Two hundred and seventy seven patients diagnosed in our i...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2011.03.019

    authors： Cedrés S,Nuñez I,Longo M,Martinez P,Checa E,Torrejón D,Felip E

    更新日期：2011-05-01 00:00:00

  • Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer.

    abstract：BACKGROUND:This study assesses the predictive and prognostic roles of serum soluble intercellular adhesion molecule-1 (sICAM-1) and vascular endothelial growth factor (VEGF) during chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:Changes in serum levels of sICAM-1 and VEG...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2011.03.009

    authors： Qian Q,Zhan P,Yu L,Shi Y,Cheng J,Wei S,Wang Q,Song Y

    更新日期：2011-03-01 00:00:00

  • Radiotherapy for stage III non-small-cell lung carcinoma in the elderly (age ≥ 70 years).

    abstract：BACKGROUND:Elderly patients are underrepresented in trials that establish definitive chemoradiotherapy as the standard of care for inoperable stage III non-small-cell lung carcinoma (NSCLC). This study analyzed radiotherapy treatment delivery and outcomes at our institution according to elderly (≥ 70 years old) or youn...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2013.05.001

    authors： Aridgides PD,Janik A,Bogart JA,Duffy S,Rosenbaum P,Gajra A

    更新日期：2013-11-01 00:00:00

  • Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08).

    abstract：INTRODUCTION:Small-cell lung cancer (SCLC) is a highly vascularized tumor. ASA404 is a tumor vascular disrupting agent. This is the first trial to report the effects of combining chemotherapy with ASA404 in SCLC. METHODS:Patients with untreated metastatic SCLC were treated with carboplatin (area under curve, 6) plus p...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.cllc.2012.04.001

    authors： Früh M,Cathomas R,Siano M,Tscherry G,Zippelius A,Mamot C,Erdmann A,Krasniqi F,Rauch D,Simcock M,Küttel E,Fustier P,Pless M,Swiss Group for Clinical Cancer Research.

    更新日期：2013-01-01 00:00:00

  • Prognostic factors in the radical nonsurgical treatment of stage IIIB non-small-cell lung cancer.

    abstract：BACKGROUND:Many patients diagnosed with stage IIIB (AJCC sixth edition; T4, N3, or both; no pleural effusion) non-small-cell lung cancer (NSCLC) are treated with curative intent, despite a low cure rate. Guidelines are required to help select patients for radical therapy so that the patients with little chance of cure ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2013.12.007

    authors： Russell K,Healy B,Pantarotto J,Laurie SA,MacRae R,Sabri E,Wheatley-Price P

    更新日期：2014-05-01 00:00:00

  • Pulmonary function tests as a predictor of quantitative and qualitative outcomes after thoracic surgery for lung cancer.

    abstract：BACKGROUND:Pulmonary function tests are used to select patients with non-small-cell lung cancer (NSCLC) suitable for thoracic surgery. We studied the impact of pulmonary function tests on both quantitative (morbidity, mortality, and overall survival [OS]) and qualitative (quality of life [QOL]) outcomes of patients und...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/CLC.2007.n.042

    authors： Greillier L,Thomas P,Loundou A,Doddoli C,Badier M,Auquier P,Barlési F

    更新日期：2007-11-01 00:00:00

  • Gemcitabine and carboplatin in advanced non small-cell lung cancer: a review.

    abstract：:Both gemcitabine and carboplatin have demonstrated activity in advanced non small-cell lung cancer. The combination of gemcitabine and cisplatin has demonstrated equivalent or superior efficacy to other commonly used agents and two-drug combinations, and a recent Eastern Cooperative Oncology Group trial suggested that...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/clc.2000.s.008

    authors： Masters GA

    更新日期：2000-12-01 00:00:00

  • Three-dimensional conformal radiation therapy (3D-CRT) for early-stage non-small-cell lung cancer.

    abstract：:The standard treatment for early-stage non-small-cell lung cancer is surgical resection. However, many patients are inoperable due to medical comorbidities. Thirty-two medically inoperable patients with early-stage non-small-cell lung cancer were treated with 3-dimensional conformal radiation therapy between January 1...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/clc.2001.n.025

    authors： Rosenzweig KE,Dladla N,Schindelheim R,Sim SE,Braban LE,Venkataraman ES,Leibel SA

    更新日期：2001-11-01 00:00:00

  • High N-terminal pro-B-type natriuretic peptide: a biomarker of lung cancer?

    abstract：BACKGROUND:The level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) is affected by many known factors. Our study aimed to evaluate whether other factors, in particular lung cancer, could be responsible for an increase in NT-proBNP levels in a population with no known risk factors for elevated NT-proBNP. PATI...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/CLC.2010.n.043

    authors： Aujollet N,Meyer M,Cailliod R,Combier F,Coignet Y,Campard S,Facy O,Bernard A,Girard C

    更新日期：2010-09-01 00:00:00

  • Maintenance or Consolidation Therapy for Non--Small-Cell Lung Cancer: A Meta-Analysis Involving 5841 Subjects.

    abstract：INTRODUCTION:Maintenance therapy is a new treatment paradigm for advanced non-small-cell lung cancer (NSCLC). We conducted a meta-analysis to evaluate its clinical efficacy in NSCLC and compared the efficacy of chemotherapy, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), and other treatment ap...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,meta分析

    doi：10.1016/j.cllc.2015.01.002

    authors： Zhang C,Huang C,Wang J,Wang X,Li K

    更新日期：2015-09-01 00:00:00